Profile assembled from Strikepoint News signal data — drill results, warrant filings, financings, insider transactions, and news. Drill rock value per tonne is the gross in-situ value at today's spot prices, recomputed live. This page is for informational purposes only and is not investment advice; verify against the original filings before drawing conclusions.
4 active warrant series covering 21,792,300 shares (~23.4% potential dilution); nearest expiry 2027-11-06.
| Type | Status | Source | |||||
|---|---|---|---|---|---|---|---|
| warrant | $0.20 | Nov 6, 2027 391d | 12.8M | OTM | 13.8% | C$2.6M | Auto |
| warrant | $0.13 | Nov 6, 2027 391d | 6K | OTM | 0.0% | C$750 | Auto |
| warrant | $0.20 | Dec 16, 2027 431d | 8.8M | OTM | 9.4% | C$1.8M | Auto |
| warrant | $0.13 | Dec 16, 2027 431d | 186K | OTM | 0.2% | C$23K | Auto |
Basis: Current shares & price vs as-filed warrant terms.
5 option grants covering 5,975,000 shares (~6.4% potential dilution). Counted apart from the warrants above.
| Type | Status | Source | |||||
|---|---|---|---|---|---|---|---|
| option | $0.15 | Apr 1, 2027 172d | 100K | OTM | 0.1% | C$15K | Auto |
| option | $0.11 | Nov 29, 2027 414d | 700K | ITM | 0.8% | C$77K | Auto |
| option | $0.15 | Dec 15, 2028 796d | 1.1M | OTM | 1.2% | C$173K | Auto |
| option | $0.16 | Jan 20, 2029 832d | 1.5M | OTM | 1.6% | C$236K | Auto |
| option | $0.16 | Jan 20, 2031 1562d | 2.5M | OTM | 2.7% | C$408K | Auto |
93,234,836 shares outstanding, plus 21,792,300 from warrants and 5,975,000 from options — a fully diluted 121,002,136 shares, or ~29.8% above today's count if every one of them is exercised.
Price history with the company's supply walls overlaid — warrants (amber), employee and consultant options (pink), and free-trading unlock dates (violet). Each wall sits at the price the paper is struck at today, restated through any consolidation, and is measured in the SHARES it can issue rather than the number of certificates. Levels and dates are Pacific Time.
An issuer that discloses only a plan total appears as one line at its weighted-average exercise price and weighted-average remaining life — the filing's own summary, not a per-grant schedule.